5-Alpha-Reductase Deficiency Clinical Presentation
- Author: Jill E Emerick, MD; Chief Editor: Stephen Kemp, MD, PhD more...
History
Diagnosis of 5-alpha-reductase type 2 deficiency (5-ARD) is usually made in the newborn period when the infant presents with ambiguous genitalia.[7] No risk factors or clinical markers in pregnancy are known. Genital ambiguity is occasionally diagnosed prenatally when an infant who is demonstrated by amniocentesis or chorionic villus sampling to have XY karyotype fails to have a demonstrable penis on ultrasonography.
If 5-alpha-reductase deficiency is considered in a newborn, a broad approach to ambiguous genitalia should be taken.[1, 6] The utmost care should be taken not to assign a gender to the child before evaluation and consultation with an experienced, multidisciplinary team. The first words spoken to the parents are likely to be remembered and should focus on the overall health of the infant. A sensitive discussion about the uncertainty of the child's gender and explanation of the child's genital anatomy can be aided by online developmental Web sites, such as the ones available on the Sick Kids and DSD Guidelines sites. See Ambiguous Genitalia and Intersexuality for more in depth discussion
Initial evaluation should begin with a careful history.[1] Assess prenatal and maternal past medical and family history. Specific questions should be asked regarding relatives with disorders of sexual development (DSDs), neonatal deaths, amenorrhea, or infertility and consanguinity. Parental consanguinity increases the child's risk for autosomal recessive disorders including 5-alpha reductase type 2 deficiency.
Physical
Workup of ambiguous genitalia must include careful physical examination to characterize the degree of virilization on the Prader scale (see the image below), presence of palpable gonadal tissue, and overall health of the child.[6]
Prader scale reflecting the degree of virilization of the external genitalia. The internal genitalia reflect the changes in the urogenital sinus in response to the presence or absence of mullerian inhibiting hormone (MIH) Neonatal presentation
Phenotypic findings in a newborn are limited to the genitalia.[7, 8] The spectrum of findings ranges from minimal undervirilization presenting with normal male anatomy, except for isolated micropenis or hypospadias, to severe undervirilization presenting as normal female external genitalia with mild clitoral enlargement as the only physical finding.
Most commonly, the external genitalia exhibit labial appearance to the labioscrotal folds with some mild rugation or pigmentation present in some patients.
The phallus is indeterminate in size. Its length falls between 1 cm (ie, usual maximum for a clitoris) and 2 cm (ie, lower limit of normal for a penis).
The urethra may empty anywhere from the tip of the phallus to the perineum, with the latter observed more often.
The testes are usually in the inguinal canals bilaterally; however, in some individuals with 5-alpha-reductase type 2 deficiency, the testes can be found in the labioscrotal folds or retained in the abdomen.
A pseudovaginal blind-ending introitus is usually present with a normal hymen.
Because the uterus is absent, rectal examination results are negative for a cervical mass.
The rest of the examination findings are within normal limits.
Presentation of males at puberty
Clear signs of virilization predominate at this age. The escutcheon is male in distribution. The phallus exhibits definite enlargement. The shoulders are relatively broad and the hips are narrow.
Muscularity and body hair may increase. No breast development is generally present. A prominent Adam's apple may start to develop. Facial hair develops. The child's voice may begin to deepen.
The mucosa of the vaginal introitus remains atrophic in appearance (remaining red) rather than the thickened pink of estrogen-stimulated mucosa.
Presentation of females
Females homozygous for 5-alpha-reductase type 2 deficiency have very subtle manifestations, such as delayed menarche, minimal acne, and minimal body hair.[9] Fertility is normal in females.
Causes
The cause of 5-alpha-reductase type 2 deficiency is the deficiency of the type 2 isozyme of 5-alpha-reductase.
As with most single enzyme disorders, 5-alpha-reductase type 2 deficiency is an autosomal recessive trait and sex limited because the clinical syndrome only affects genetic males, with very subtle phenotypic findings in homozygous females.[10]
[Guideline] Houk CP, Lee PA. Consensus statement on terminology and management: disorders of sex development. Sex Dev. 2008;2(4-5):172-80. [Medline].
Silver RI, Russell DW. 5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias. J Urol. Sep 1999;162(3 Pt 2):1142-5. [Medline].
Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. Dec 30 2002;198(1-2):51-9. [Medline].
Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. Feb 2009;1155:43-56. [Medline].
Medonca BB, Domenice S, Arnhold, JP, and Costa EMF. 46, XY disorders of sex development (DSD). Clinical Endocrinology. 2009;70:173-187.
Allen L. Disorders of Sexual Development. Obstet Gynecol Clin N Am. 2009;36:25-45.
Bertelloni S, Scaramuzzo RT, Parrini D, Baldinotti F, Tumini S, Ghirri P. Early diagnosis of 5alpha-reductase deficiency in newborns. Sex Dev. 2007;1(3):147-51. [Medline].
Praveen EP, Desai AK, Khurana ML, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab. Feb 2008;21(2):173-9. [Medline].
Katz MD, Cai LQ, Zhu YS, et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab. Nov 1995;80(11):3160-7. [Medline].
Choi JH, Kim GH, Seo EJ, Kim KS, Kim SH, Yoo HW. Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development. J Pediatr Endocrinol Metab. Jun 2008;21(6):545-53. [Medline].
hCG Stimulation Test v2. Available at www.dvh.nhs.uk/downloads/documents/5K1WT1DN2U_hCG_Stimulation_Test_v2.pdf. Accessed 11/09/2009.
Informed Consent for Pediatric Genitoplasty or Gonadectomy in Patients with DSDs. AIC Legal. Available at http://www.lgbtbar.org/annual/CLE_materials/3B/GuidelinesforInformedConsent.pdf. Accessed 11/04/2009.
Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore). Mar 1996;75(2):64-76. [Medline].
Price P, Wass JA, Griffin JE, et al. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha- reductase deficiency and disorders of the androgen receptor. J Clin Invest. Oct 1984;74(4):1496-508. [Medline].
Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab. Aug 2006;91(8):3017-23. [Medline].
Sharma S, K Gupta D. Male genitoplasty for intersex disorders. Adv Urol. 2008;685897. [Medline].
Ghanem H, Shamloul R, Khodeir F, ElShafie H, Kaddah A, Ismail I. Structured management and counseling for patients with a complaint of a small penis. J Sex Med. Sep 2007;4(5):1322-7. [Medline].
Vardi Y, Har-Shai Y, Gil T, Gruenwald I. A critical analysis of penile enhancement procedures for patients with normal penile size: surgical techniques, success, and complications. Eur Urol. Nov 2008;54(5):1042-50. [Medline].
Katz MD, Kligman I, Cai LQ, et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med. Apr 3 1997;336(14):994-7. [Medline].
Wilson BE, Reiner WG. Management of intersex: a shifting paradigm. J Clin Ethics. Winter 1998;9(4):360-9. [Medline].
Tamar-Mattis A. Medical decision making adn the child with a DSD. www.endocrinetoday.com. Available at http://www.endocrinetoday.com/view.aspx?rid=32542. Accessed 11/05/2009.
Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. Aug 2005;34(4):399-410. [Medline].
hCG Stimulation Test. Available at www.dvh.nhs.uk/downloads/documents/5K1WT1DN2U_hCG_Stimulation_Test_v2.pdf. Accessed 11/09/2009.

